Literature DB >> 23513480

Successful medical treatment in a child with E. coli ESBL meningitis with acute communicating hydrocephalus and ventricular empyema: a case report.

Chanapai Chaiyakulsil1, Olarn Prommalikit.   

Abstract

Extended-spectrum beta-lactamase (ESBL) producing organisms cause wide spectrum of diseases including urinary tract infection, cholangitis, intra-abdominal abscess or pneumonia but rarely meningitis. The present report a successful nonsurgical, medical treatment in a child with Escherichia coli ESBL meningitis with acute symptomatic communicating hydrocephalus and ventricular empyema. Incidence of infections from ESBL producing organisms are increasingly emerging and causing wide spectrum of illnesses which prompts for both aggressive medical and surgical intervention to prevent morbidity and mortality. Antimicrobial agents must be vigilantly utilized to prevent possible development of new highly-resistant organisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23513480

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  4 in total

1.  Distribution of strain type and antimicrobial susceptibility of Escherichia coli isolates causing meningitis in a large urban setting in Brazil.

Authors:  Hillary Berman; Maria Goreth Barberino; Edson Duarte Moreira; Lee Riley; Joice N Reis
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

2.  ESBL Escherichia coli Ventriculitis after Aneurysm Clipping: A Rare and Difficult Therapeutic Challenge.

Authors:  F A Zeiler; J Silvaggio
Journal:  Case Rep Neurol Med       Date:  2015-04-29

3.  Neuroinvasive Infection from O117:K52:H-Escherichia coli following Acute Pyelonephritis.

Authors:  H Cromlin; H Rodriguez-Villalobos; A Deplano; T Duprez; P Hantson
Journal:  Case Rep Infect Dis       Date:  2017-11-26

4.  Extended-spectrum Beta-lactamase-producing Escherichia coli Meningitis That Developed from Otitis Media with Cholesteatoma.

Authors:  Motofumi Tosa; Masako Aihara; Junko Murakami
Journal:  Intern Med       Date:  2018-06-06       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.